On-therapy HBsAg kinetics can predict HBsAg loss after nucleos(t)ide analogues interruption in HBeAg-negative patients. The cup is half full and half empty

Background: Nucleos(t)ide analogues withdrawal may improve HBsAg loss rates. However, conditions to select patients are not well established. Aims: to evaluate the impact of HBsAg kinetics before treatment interruption on post-treatment response. Methods: Longitudinal, ambispective study in non-cirr...

Descripción completa

Detalles Bibliográficos
Autores: Broquetas, Teresa, Hernández, Juan José, García Retortillo, Montserrat, Canillas, Lidia, Puigvehí, Marc, Cañete Hidalgo, Nuria, Coll Estrada, Susanna, Viu, Ana, Garrido, Esther, Micó, Miquel, Bessa i Caserras, Xavier, Carrión Rodríguez, José Antonio
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10230/54059
Acceso en línea:http://hdl.handle.net/10230/54059
http://dx.doi.org/10.1016/j.dld.2021.12.017
Access Level:acceso abierto
Palabra clave:Antiviral
HBsAg
Hepatitis B
Kinetics
id ES_9376281f0eb4fd0fc97a71bcb140c989
oai_identifier_str oai:recercat.cat:10230/54059
network_acronym_str ES
network_name_str España
repository_id_str
spelling On-therapy HBsAg kinetics can predict HBsAg loss after nucleos(t)ide analogues interruption in HBeAg-negative patients. The cup is half full and half emptyBroquetas, TeresaHernández, Juan JoséGarcía Retortillo, MontserratCanillas, LidiaPuigvehí, MarcCañete Hidalgo, NuriaColl Estrada, SusannaViu, AnaGarrido, EstherMicó, MiquelBessa i Caserras, XavierCarrión Rodríguez, José AntonioAntiviralHBsAgHepatitis BKineticsBackground: Nucleos(t)ide analogues withdrawal may improve HBsAg loss rates. However, conditions to select patients are not well established. Aims: to evaluate the impact of HBsAg kinetics before treatment interruption on post-treatment response. Methods: Longitudinal, ambispective study in non-cirrhotic chronic hepatitis B HBeAg-negative patients, analysing on-treatment and post-treatment HBsAg kinetics. On-treatment HBsAg kinetics diagnostic accuracy (AUROC) to identify HBsAg loss was evaluated. Results: 52 HBeAg-negative patients stopped treatment after 8.2 years, and 6 (11.5%) achieved HBsAg loss one year after withdrawal. Multivariate analysis showed that on-treatment HBsAg kinetics was related to HBsAg loss (OR=0.10; 95%CI=0.016-0.632; p = 0.014) with a high diagnostic accuracy (AUROC=0.935). A significant HBsAg decline ≥1 log10 IU/mL showed a positive and negative predictive value of 50% and of 97.6%, respectively. After treatment interruption, HBsAg decline speed (log10 IU/mL/year) accelerated in patients treated >6 years (from -0.06 to -0.20, p<0.05) and remained stable in treated <6 years (from -0.12 to -0.12 p=ns). Conclusions: On-treatment HBsAg kinetics can predict post-treatment HBsAg loss rate. Half of patients with a significant HBsAg decline can eliminate HBsAg the first year after withdrawal. Post-treatment HBsAg decline is faster not only in patients who lost the HBsAg but also in those who remain HBsAg-positive.Elsevier202220222022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/54059http://dx.doi.org/10.1016/j.dld.2021.12.017reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésDig Liver Dis. 2022 Aug;54(8):1044-51© 2022 The Authors. Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)http://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:10230/540592026-05-29T05:05:01Z
dc.title.none.fl_str_mv On-therapy HBsAg kinetics can predict HBsAg loss after nucleos(t)ide analogues interruption in HBeAg-negative patients. The cup is half full and half empty
title On-therapy HBsAg kinetics can predict HBsAg loss after nucleos(t)ide analogues interruption in HBeAg-negative patients. The cup is half full and half empty
spellingShingle On-therapy HBsAg kinetics can predict HBsAg loss after nucleos(t)ide analogues interruption in HBeAg-negative patients. The cup is half full and half empty
Broquetas, Teresa
Antiviral
HBsAg
Hepatitis B
Kinetics
title_short On-therapy HBsAg kinetics can predict HBsAg loss after nucleos(t)ide analogues interruption in HBeAg-negative patients. The cup is half full and half empty
title_full On-therapy HBsAg kinetics can predict HBsAg loss after nucleos(t)ide analogues interruption in HBeAg-negative patients. The cup is half full and half empty
title_fullStr On-therapy HBsAg kinetics can predict HBsAg loss after nucleos(t)ide analogues interruption in HBeAg-negative patients. The cup is half full and half empty
title_full_unstemmed On-therapy HBsAg kinetics can predict HBsAg loss after nucleos(t)ide analogues interruption in HBeAg-negative patients. The cup is half full and half empty
title_sort On-therapy HBsAg kinetics can predict HBsAg loss after nucleos(t)ide analogues interruption in HBeAg-negative patients. The cup is half full and half empty
dc.creator.none.fl_str_mv Broquetas, Teresa
Hernández, Juan José
García Retortillo, Montserrat
Canillas, Lidia
Puigvehí, Marc
Cañete Hidalgo, Nuria
Coll Estrada, Susanna
Viu, Ana
Garrido, Esther
Micó, Miquel
Bessa i Caserras, Xavier
Carrión Rodríguez, José Antonio
author Broquetas, Teresa
author_facet Broquetas, Teresa
Hernández, Juan José
García Retortillo, Montserrat
Canillas, Lidia
Puigvehí, Marc
Cañete Hidalgo, Nuria
Coll Estrada, Susanna
Viu, Ana
Garrido, Esther
Micó, Miquel
Bessa i Caserras, Xavier
Carrión Rodríguez, José Antonio
author_role author
author2 Hernández, Juan José
García Retortillo, Montserrat
Canillas, Lidia
Puigvehí, Marc
Cañete Hidalgo, Nuria
Coll Estrada, Susanna
Viu, Ana
Garrido, Esther
Micó, Miquel
Bessa i Caserras, Xavier
Carrión Rodríguez, José Antonio
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Antiviral
HBsAg
Hepatitis B
Kinetics
topic Antiviral
HBsAg
Hepatitis B
Kinetics
description Background: Nucleos(t)ide analogues withdrawal may improve HBsAg loss rates. However, conditions to select patients are not well established. Aims: to evaluate the impact of HBsAg kinetics before treatment interruption on post-treatment response. Methods: Longitudinal, ambispective study in non-cirrhotic chronic hepatitis B HBeAg-negative patients, analysing on-treatment and post-treatment HBsAg kinetics. On-treatment HBsAg kinetics diagnostic accuracy (AUROC) to identify HBsAg loss was evaluated. Results: 52 HBeAg-negative patients stopped treatment after 8.2 years, and 6 (11.5%) achieved HBsAg loss one year after withdrawal. Multivariate analysis showed that on-treatment HBsAg kinetics was related to HBsAg loss (OR=0.10; 95%CI=0.016-0.632; p = 0.014) with a high diagnostic accuracy (AUROC=0.935). A significant HBsAg decline ≥1 log10 IU/mL showed a positive and negative predictive value of 50% and of 97.6%, respectively. After treatment interruption, HBsAg decline speed (log10 IU/mL/year) accelerated in patients treated >6 years (from -0.06 to -0.20, p<0.05) and remained stable in treated <6 years (from -0.12 to -0.12 p=ns). Conclusions: On-treatment HBsAg kinetics can predict post-treatment HBsAg loss rate. Half of patients with a significant HBsAg decline can eliminate HBsAg the first year after withdrawal. Post-treatment HBsAg decline is faster not only in patients who lost the HBsAg but also in those who remain HBsAg-positive.
publishDate 2022
dc.date.none.fl_str_mv 2022
2022
2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/54059
http://dx.doi.org/10.1016/j.dld.2021.12.017
url http://hdl.handle.net/10230/54059
http://dx.doi.org/10.1016/j.dld.2021.12.017
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Dig Liver Dis. 2022 Aug;54(8):1044-51
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869413599075631104
score 15,812429

Similares en LA Referencia